ZyVersa Therapeutics, Inc.
ZVSA· OTC
Filed Mar 25, 2024 · 10-K · 85 days after period end · 0001493152-24-011073
derived · Computed from the longer spans the company filed.
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures |
|---|---|---|
| Net Income | -$13.34M | -$12.25M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ZyVersa Therapeutics, Inc. · CIK 1859007 · Engraved from SEC EDGAR
ended Dec 31, 2023 · filed Mar 25, 2024 · 85 d after period end